HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCPSA Recast Offers Small-Biz Concessions, Gains New Industry Support

This article was originally published in The Rose Sheet

Executive Summary

The recast of the Personal Care Products Safety Act includes new exemptions and revised fee expectations for the smallest cosmetics businesses, winning support from their trade groups. But the Independent Cosmetic Manufacturers and Distributors, whose members range in size up to Mary Kay, still finds the bill's proposed regulatory framework too burdensome to get behind.

You may also be interested in...

ICMAD Stands By House Cosmetics Bill, But May Be Ready To Negotiate

The Independent Cosmetic Manufacturers and Distributors calls Republican Senator Orrin Hatch's FDA Cosmetic Safety and Modernization Act "a step in the right direction," echoing the Personal Care Products Council's take on the proposal, signaling potential for industry solidarity at an auspicious moment in Washington.

Former FDA Commish Califf Advocates Cosmetics Registration, AE Reporting

FDA is hampered in its public safety mission under current law, which does not require cosmetics firms to register marketed products or report adverse events, former agency head Robert Califf says. His June 26 editorial in Jama Internal Medicine accompanies an analysis of FDA's cosmetics adverse-event data.

FDA To Curtail Cosmetics Safety Work Under FY 2018 Budget Constraints

President Trump's budget proposal for fiscal 2018 calls for "targeted reductions to the Food Safety program, including reducing staff levels through attrition." In its justification to congressional appropriators, FDA says it will reduce funding for cosmetics safety work in order to focus on top priorities in the broad foods area.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts